Turner, Steve W
Richardson, Kathryn
Burden, Annie
Thomas, Mike
Murray, Clare
Price, David
Article History
Received: 22 December 2014
Revised: 3 April 2015
Accepted: 7 April 2015
First Online: 11 June 2015
Competing interests
: MT: Neither MT nor any member of his close family has any shares in pharmaceutical companies. In the last 3 years he has received speaker’s honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: Aerocrine, Astra Zeneca, Boehringer Inglehiem, GSK, MSD, and Teva. He has received honoraria for attending advisory panels with; Aerocrine, Almirall, Astra Zeneca, BI, Chiesi, GSK, MSD, and Novartis. He has received sponsorship to attend international scientific meetings from: GSK, Astra Zeneca, and Mundipharma. He has received funding for research projects from: GSK and Almirall. He is a chief medical adviser to the charity Asthma UK, a member of the BTS SIGN Asthma guideline group and the NICE Asthma guideline group. DP: board Membership: Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva. Consultancy: Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, and Teva. Grants/Grants Pending: UK National Health Service, British Lung Foundation, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, Mundipharma, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva, and Zentiva. Payments for lectures/speaking: Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, Takeda, and Teva. Payment for manuscript preparation: Mundipharma and Teva. Patents (planned, pending or issued): AKL. Payment for the development of educational materials: GSK and Novartis. Stock/Stock options: Shares in AKL which produces phytopharmaceuticals and owns 80% of Research in Real Life and its subsidiary social enterprise Optimum Patient Care. Payment for travel/accommodations/meeting expenses: Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva. Funding for patient enrolment or completion of research: Almirall, Chiesi, Teva, and Zentiva. Peer reviewer for grant committees: Medical Research Council (2014), Efficacy and Mechanism Evaluation programme (2012), and HTA (2014). Unrestricted funding for investigator-initiated studies: Aerocrine, AKL, Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, and Zentiva. AB is an employee of RiRL, which has conducted paid research in respiratory disease on behalf of the following organisations in the past 5 years: Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, and Zentiva. ST, CM, and KR have no conflicts of interest to declare.